Alvotech Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Alvotech kazanç ve gelirinin sırasıyla yıllık 101.4% ve 35.3% oranında artması tahmin edilirken, EPS'nin yıllık 102.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

101.4%

Kazanç büyüme oranı

102.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	0%
Gelir büyüme oranı	35.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

ICSE:ALVO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	909	191	378	378	2
12/31/2025	643	43	218	218	4
12/31/2024	408	-130	110	110	4
6/30/2024	309	-618	-343	-310	N/A
3/31/2024	114	-494	-339	-301	N/A
12/31/2023	93	-552	-359	-312	N/A
9/30/2023	64	-596	-356	-309	N/A
6/30/2023	65	-416	-347	-299	N/A
3/31/2023	100	-713	-411	-361	N/A
12/31/2022	85	-514	-361	-312	N/A
9/30/2022	96	61	-388	-319	N/A
6/30/2022	78	-12	-345	-285	N/A
3/31/2022	39	-42	-274	-223	N/A
12/31/2021	40	-102	-269	-228	N/A
12/31/2020	69	-170	-86	-74	N/A
12/31/2019	83	-210	-97	-89	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ALVO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 5.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ALVO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ALVO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ALVO şirketinin gelirinin (yıllık 35.3% ) IS pazarından (yıllık 4.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ALVO şirketinin gelirinin (yıllık 35.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ALVO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Alvotech Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Recent updates

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Alvotech Announces Executive Changes

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Alvotech to Report Q1, 2023 Results on May 18, 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$2.60 loss per share (vs US$0.92 loss in FY 2021)

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Alvotech Announces Executive Changes

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Initiates Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech to Report Q2, 2022 Results on Aug 31, 2022

Alvotech Initiates Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Expands its Board of Directors as Part of Transition from Private to Publicly Traded Company

Alvotech Initiates Patient Study for AVT06

No independent directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri